We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

BioTek

BioTek Instruments, Inc., designs, manufactures, and distributes life science instrumentation. Its product line inclu... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification

By LabMedica International staff writers
Posted on 19 Aug 2015
Print article
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).
A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major manufacturer of HTRF reagents.

HTRF involves several carefully selected fluorophores. Fluorescence resonance energy transfer (FRET) partners must fulfill multiple compatibility criteria. First, their emission spectra must show non-overlapping regions in order to be able to measure each partner's fluorescence individually. Second, the FRET quantum yield (i.e., its efficacy) must be as high as possible. Third, fluorescence emission must occur within a region of the spectrum remote from that naturally produced by proteins; in other words, a red-shifted emission is theoretically better in order to avoid medium-intrinsic fluorescence. HTRF uses a combination of several fluorophores forming different FRET systems. HTRF's central element, the energy donor, consists of a rare earth complex in which the lanthanide ion (europium or terbium) is tightly embedded in a macrocycle. This very unique type of structure gives HTRF donors their long-lived fluorescence properties, as well as robustness that enables these molecules to be used in most assay conditions.

In order to broaden HTRF readout capabilities for use in the field of life sciences, Cisbio Bioassays (Codolet, France) has initiated partnerships with several detection system manufacturers. This collaboration has led to high standard reader certification, indicated by an HTRF sticker. This label guarantees that the reader meets the physical specifications for optimal HTRF readout.

Cisbio recently added the BioTek (Winooski, VT, USA) Synergy Neo2 Multi-Mode Reader to the list of instruments with HTRF certification.

The Synergy Neo2 Multi-Mode Reader was designed for speed and ultra-high quality performance. It incorporates BioTek's patented Hybrid technology, which combines independent monochromator-based and filter-based optics in the same instrument. Thus, continuously variable bandwidth quadruple monochromators, sensitive high transmission filter-based optics, and up to four photomultiplier tubes provide ultra-fast measurements with high quality results.

Complementing its sophisticated optic systems, the Synergy Neo2 boasts advanced environment controls, including CO2/O2 control and incubation up to 65 degrees Celsius. Variable shaking supports live cell assays, while cell-based detection is optimized with direct bottom illumination.

The instrument package is powered by BioTek's Gen5 Data Analysis Software and has been configured to integrate seamlessly with the optional BioStackNeo plate stacker, which was designed specifically for use with the Synergy Neo2.

Gary Barush, director of marketing and sales at BioTek, said, “For years BioTek has led the evolution of multimode detection. We are proud to introduce this top-of-the-line reader which combines best in class performance in all modes with the speed that customers demand. In addition to being optimized for biochemical assay performance, Synergy Neo2 provides unsurpassed results for cell based assay detection, while its modular configuration makes this new level of performance accessible for many budgets."

Related Links:

Cisbio Bioassays
BioTek


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.